Cargando…

Endometrial PTEN Deficiency Leads to SMAD2/3 Nuclear Translocation

SIMPLE SUMMARY: PTEN is a protein highly altered in endometrial cancer. PTEN mutation or deficiency leads to the activation of other downstream proteins that are important to the development of cancers. In this study, we have identified the SMAD2/3 proteins as targets of PTEN deficiency. We have fou...

Descripción completa

Detalles Bibliográficos
Autores principales: Eritja, Núria, Navaridas, Raúl, Ruiz-Mitjana, Anna, Vidal-Sabanés, Maria, Egea, Joaquim, Encinas, Mario, Matias-Guiu, Xavier, Dolcet, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507901/
https://www.ncbi.nlm.nih.gov/pubmed/34638474
http://dx.doi.org/10.3390/cancers13194990
_version_ 1784581969444601856
author Eritja, Núria
Navaridas, Raúl
Ruiz-Mitjana, Anna
Vidal-Sabanés, Maria
Egea, Joaquim
Encinas, Mario
Matias-Guiu, Xavier
Dolcet, Xavier
author_facet Eritja, Núria
Navaridas, Raúl
Ruiz-Mitjana, Anna
Vidal-Sabanés, Maria
Egea, Joaquim
Encinas, Mario
Matias-Guiu, Xavier
Dolcet, Xavier
author_sort Eritja, Núria
collection PubMed
description SIMPLE SUMMARY: PTEN is a protein highly altered in endometrial cancer. PTEN mutation or deficiency leads to the activation of other downstream proteins that are important to the development of cancers. In this study, we have identified the SMAD2/3 proteins as targets of PTEN deficiency. We have found that loss of PTEN in endometrial cells leads to SMAD2/3 activation. To investigate the role of SMAD2/3 activation downstream of PTEN deficiency, we have used endometrial cells lacking both PTEN and SMAD2/3 proteins. These cells display even more tumorigenic potential than cells lacking only PTEN. These results suggest that SMAD2/3 acts as an obstacle for cancer development triggered by PTEN loss. ABSTRACT: TGF-β has a dichotomous function, acting as tumor suppressor in premalignant cells but as a tumor promoter for cancerous cells. These contradictory functions of TGF-β are caused by different cellular contexts, including both intracellular and environmental determinants. The TGF-β/SMAD and the PI3K/PTEN/AKT signal transduction pathways have an important role in the regulation of epithelial cell homeostasis and perturbations in either of these two pathways’ contributions to endometrial carcinogenesis. We have previously demonstrated that both PTEN and SMAD2/3 display tumor-suppressive functions in the endometrium, and genetic ablation of either gene results in sustained activation of PI3K/AKT signaling that suppresses TGF-β-induced apoptosis and enhances cell proliferation of mouse endometrial cells. However, the molecular and cellular effects of PTEN deficiency on TGF-β/SMAD2/3 signaling remain controversial. Here, using an in vitro and in vivo model of endometrial carcinogenesis, we have demonstrated that loss of PTEN leads to a constitutive SMAD2/3 nuclear translocation. To ascertain the function of nuclear SMAD2/3 downstream of PTEN deficiency, we analyzed the effects of double deletion PTEN and SMAD2/3 in mouse endometrial organoids. Double PTEN/SMAD2/3 ablation results in a further increase of cell proliferation and enlarged endometrial organoids compared to those harboring single PTEN, suggesting that nuclear translocation of SMAD2/3 constrains tumorigenesis induced by PTEN deficiency.
format Online
Article
Text
id pubmed-8507901
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85079012021-10-13 Endometrial PTEN Deficiency Leads to SMAD2/3 Nuclear Translocation Eritja, Núria Navaridas, Raúl Ruiz-Mitjana, Anna Vidal-Sabanés, Maria Egea, Joaquim Encinas, Mario Matias-Guiu, Xavier Dolcet, Xavier Cancers (Basel) Article SIMPLE SUMMARY: PTEN is a protein highly altered in endometrial cancer. PTEN mutation or deficiency leads to the activation of other downstream proteins that are important to the development of cancers. In this study, we have identified the SMAD2/3 proteins as targets of PTEN deficiency. We have found that loss of PTEN in endometrial cells leads to SMAD2/3 activation. To investigate the role of SMAD2/3 activation downstream of PTEN deficiency, we have used endometrial cells lacking both PTEN and SMAD2/3 proteins. These cells display even more tumorigenic potential than cells lacking only PTEN. These results suggest that SMAD2/3 acts as an obstacle for cancer development triggered by PTEN loss. ABSTRACT: TGF-β has a dichotomous function, acting as tumor suppressor in premalignant cells but as a tumor promoter for cancerous cells. These contradictory functions of TGF-β are caused by different cellular contexts, including both intracellular and environmental determinants. The TGF-β/SMAD and the PI3K/PTEN/AKT signal transduction pathways have an important role in the regulation of epithelial cell homeostasis and perturbations in either of these two pathways’ contributions to endometrial carcinogenesis. We have previously demonstrated that both PTEN and SMAD2/3 display tumor-suppressive functions in the endometrium, and genetic ablation of either gene results in sustained activation of PI3K/AKT signaling that suppresses TGF-β-induced apoptosis and enhances cell proliferation of mouse endometrial cells. However, the molecular and cellular effects of PTEN deficiency on TGF-β/SMAD2/3 signaling remain controversial. Here, using an in vitro and in vivo model of endometrial carcinogenesis, we have demonstrated that loss of PTEN leads to a constitutive SMAD2/3 nuclear translocation. To ascertain the function of nuclear SMAD2/3 downstream of PTEN deficiency, we analyzed the effects of double deletion PTEN and SMAD2/3 in mouse endometrial organoids. Double PTEN/SMAD2/3 ablation results in a further increase of cell proliferation and enlarged endometrial organoids compared to those harboring single PTEN, suggesting that nuclear translocation of SMAD2/3 constrains tumorigenesis induced by PTEN deficiency. MDPI 2021-10-05 /pmc/articles/PMC8507901/ /pubmed/34638474 http://dx.doi.org/10.3390/cancers13194990 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Eritja, Núria
Navaridas, Raúl
Ruiz-Mitjana, Anna
Vidal-Sabanés, Maria
Egea, Joaquim
Encinas, Mario
Matias-Guiu, Xavier
Dolcet, Xavier
Endometrial PTEN Deficiency Leads to SMAD2/3 Nuclear Translocation
title Endometrial PTEN Deficiency Leads to SMAD2/3 Nuclear Translocation
title_full Endometrial PTEN Deficiency Leads to SMAD2/3 Nuclear Translocation
title_fullStr Endometrial PTEN Deficiency Leads to SMAD2/3 Nuclear Translocation
title_full_unstemmed Endometrial PTEN Deficiency Leads to SMAD2/3 Nuclear Translocation
title_short Endometrial PTEN Deficiency Leads to SMAD2/3 Nuclear Translocation
title_sort endometrial pten deficiency leads to smad2/3 nuclear translocation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507901/
https://www.ncbi.nlm.nih.gov/pubmed/34638474
http://dx.doi.org/10.3390/cancers13194990
work_keys_str_mv AT eritjanuria endometrialptendeficiencyleadstosmad23nucleartranslocation
AT navaridasraul endometrialptendeficiencyleadstosmad23nucleartranslocation
AT ruizmitjanaanna endometrialptendeficiencyleadstosmad23nucleartranslocation
AT vidalsabanesmaria endometrialptendeficiencyleadstosmad23nucleartranslocation
AT egeajoaquim endometrialptendeficiencyleadstosmad23nucleartranslocation
AT encinasmario endometrialptendeficiencyleadstosmad23nucleartranslocation
AT matiasguiuxavier endometrialptendeficiencyleadstosmad23nucleartranslocation
AT dolcetxavier endometrialptendeficiencyleadstosmad23nucleartranslocation